Cullinan Therapeutics (CGEM)
12.05
0.00 (0.00%)
Upcoming Events
Latest Headlines
William Blair on Cullinan Oncology Inc. (CGEM): 'We continue to see multiple opportunities for upside to Cullinan shares'
June 10, 2026 4:14 PM - StreetInsider
Cullinan Oncology Inc. (CGEM) PT Raised to $46 at Clear Street
June 10, 2026 4:10 PM - StreetInsider
Cullinan Therapeutics reports clinical trial data for autoimmune treatments
June 10, 2026 7:30 AM - StreetInsider
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
June 10, 2026 7:30 AM - StreetInsider
Cullinan Therapeutics reports positive CLN-978 data at EULAR 2026
June 6, 2026 6:33 AM - StreetInsider
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
June 6, 2026 5:15 AM - StreetInsider
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
May 26, 2026 7:00 AM - StreetInsider
Cullinan Therapeutics receives FDA orphan drug status for leukemia drug
May 19, 2026 7:01 AM - StreetInsider
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
May 19, 2026 7:00 AM - StreetInsider
Cullinan Oncology (CGEM) Reiterated at Buy by Stifel on CLN-978 Data
May 19, 2026 6:51 AM - StreetInsider
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
May 18, 2026 5:00 PM - Globe NewsWire
The Biology Came First.
May 18, 2026 8:34 AM - BizWire
Cullinan Oncology, Inc. (CGEM) Tops Q1 EPS by 8c
May 7, 2026 7:10 AM - StreetInsider
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026 7:00 AM - Globe NewsWire
Form 4 Cullinan Therapeutics, For: May 05 Filed by: Michaelson Jennifer
May 6, 2026 5:01 PM - SEC Filing
Cullinan Oncology Inc. (CGEM) PT Raised to $30 at H.C. Wainwright
April 28, 2026 12:09 PM - StreetInsider
Cullinan Therapeutics (CGEM) files mixed shelf
April 28, 2026 7:54 AM - StreetInsider
FDA accepts drug application for zipalertinib lung cancer treatment
April 28, 2026 7:00 AM - StreetInsider
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
April 28, 2026 7:00 AM - BizWire
Jones Trading Assumes Cullinan Oncology Inc. (CGEM) at Buy
April 6, 2026 4:16 PM - StreetInsider
Clear Street Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
March 24, 2026 3:02 PM - StreetInsider
Full Article List
